China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.
Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.
Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments